Lee and colleagues develop anti-TLR2 nanobodies and scFvs and establish a PLGA-nanoparticle-mediated gene therapy platform for sustained antibody expression. A single intrathecal injection of these PLGA nanoparticles reduces spinal inflammatory responses and provides durable analgesia in a mouse model of neuropathic pain.